Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder

NCT07323784 is registered in ClinicalTrials.gov with Newleos Therapeutics, Inc. as lead sponsor.

NCT NCT07323784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07323784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Lead sponsor
Newleos Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 9, 2025
Completion date
January 31, 2027
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder (sad)